In the benchmark T47D ER+HER2− breast cancer CDX model, fulvestrant monotherapy provided a moderate level of tumor growth control, whereas low-dose STX-478 monotherapy and high-dose alpelisib resulted in tumor stasis. This evidence concerns the gene ESR1 and neoplasm.